Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Meta-Analysis Sheds Light on Treatment-Related AEs for PD-1 and PD-L1 Inhibitors

May 22nd 2019

Two in 3 patients treated with PD-1 or PD-L1 inhibitors experienced at least 1 AE and 1 in 7 patients experienced at least 1 grade ≥3 AE, according to a systematic review and meta-analysis of clinical trials and study updates published through December 15, 2018.

Optimal Sequencing Next Step Following Rapid Progress in HCC

May 22nd 2019

Gazala N. Khan, MD, highlights the recent headway made in hepatocellular carcinoma and discusses the remaining challenges.

Encorafenib, Binimetinib, and Cetuximab Triplet Improves OS, ORR in BRAF+ CRC

May 21st 2019

The triplet regimen of encorafenib, binimetinib, and cetuximab led to a 48% reduction in the risk of death compared with cetuximab and irinotecan-containing regimens in patients with BRAF V600E-mutant metastatic colorectal cancer who previously received up to 2 lines of therapy, meeting both primary endpoints of the phase III BEACON CRC trial.

Dr. Musher Discusses the Role of Regorafenib in Advanced HCC

May 21st 2019

Benjamin Leon Musher, MD, associate professor of medicine, hematology and oncology, at Baylor College of Medicine, discusses the role of regorafenib in the treatment of patients with advanced hepatocellular carcinoma.

Dr. Kopetz on the Biology of Right- Versus Left-Sided CRC

May 21st 2019

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the biology of right- versus left-sided colorectal cancer.

Expert Highlights Advances With Locoregional Therapies in HCC

May 21st 2019

Emil Cohen, MD, discusses the locoregional therapies available for the treatment of patients with hepatocellular carcinoma and offers insight into optimal strategies.

Dr. Philip Discusses Research Questions With Lutathera in NETs

May 20th 2019

Philip A. Philip, MD, PhD, FRCP, professor, Department of Oncology, Barbara Ann Karmanos Cancer Institute, discusses research questions with Lutathera in the treatment of patients with neuroendocrine tumors.

Shedding Light on the Challenging Pancreatic Cancer Paradigm

May 20th 2019

Vaibhav Sahai, MBBS, sheds light on ongoing research in metastatic pancreatic cancer and discusses the role of genomic profiling in the space.

Emerging CRC Treatments Highlight Need for Biomarker Testing

May 19th 2019

With multiple biomarker-directed clinical trials for metastatic CRC expected to produce data within the next few years, experts in gastrointestinal oncology who took part in a recent OncLive Peer Exchange® program recommended that clinicians become more proactive about incorporating genomic and immune markers into their decision making.

Dr. Shields on the Standard of Care in Newly Diagnosed mCRC

May 18th 2019

Anthony Shields, MD, PhD, oncologist, Department of Oncology, Molecular Imaging and Diagnostics Program, Barbara Ann Karmanos Cancer Institute, discusses the standard of care in patients with newly diagnosed metastatic colorectal cancer (mCRC).

Navigating Complexities of Localized Pancreatic Cancer, NETs

May 17th 2019

Philip A. Philip, MD, PhD, FRCP, discusses recent studies that have impacted locally advanced pancreatic cancer treatment and shared key updates in the neuroendocrine tumors paradigm.

Dr. Khan Discusses Sequencing Strategies in Advanced HCC

May 17th 2019

Gazala N. Khan, MD, gastrointestinal medical oncologist, Henry Ford Health System, discusses sequencing strategies in advanced hepatocellular carcinoma.

Ivosidenib Improves PFS in IDH1-Mutant Cholangiocarcinoma

May 16th 2019

Ivosidenib demonstrated a statistically significant improvement in progression-free survival by independent radiology review compared with placebo in patients with IDH1-mutant previously treated cholangiocarcinoma.

Shields Sheds Light on Complex mCRC Landscape

May 16th 2019

Anthony Shields, MD, PhD, shares recent efforts being made with immunotherapy research in colorectal cancer, stressed the importance of molecular testing, and shed light on the use of liquid biopsies in the space.

Lower-Dose Chemotherapy Regimen Benefits Elderly, Frail Patients with Gastroesophageal Cancer

May 16th 2019

A lower dose of oxaliplatin and capecitabine had comparable efficacy and minimized adverse events in elderly and frail patients with advanced gastroesophageal cancer.

Dr. Musher on Investigational Combination Therapies in HCC

May 16th 2019

Benjamin Leon Musher, MD, associate professor of medicine, hematology and oncology, at Baylor College of Medicine, discusses emerging combination therapies in hepatocellular carcinoma (HCC).

Dr. Mizrahi on the Importance of Early Genomic Testing in CRC

May 15th 2019

Jonathan Mizrahi, MD, a hematology/oncology fellow at The University of Texas MD Anderson Cancer Center, discusses the importance of early genomic testing in patients with colorectal cancer.

Leveraging Locoregional Therapy and Resection in Metastatic CRC

May 15th 2019

Bassel El-Rayes, MD, further discusses the role of locoregional approaches in borderline and unresectable patients with metastatic colorectal cancer.

TLR Agonists Emerge as Potential New Partner for Checkpoint Inhibitors

May 15th 2019

Toll-like receptors, a group of proteins that are components of innate immunity, are emerging as promising targets in a new wave of immunotherapies under development.

Molecular Advances in Colorectal Cancer Are "Only the Tip of the Iceberg"

May 14th 2019

There has been a significant evolution in the care of patients with metastatic colorectal cancer over the past 20 years. However, this is only the tip of the iceberg and we are going to see more and more subgroups being defined and refined with many more rationally targeted agents matching these alterations.